Recombinant Human ALCAM (C-Fc)

Description

EnkiLife provides the Recombinant Human ALCAM (C-Fc) protein,aslo know as CD166 antigen,Activated leukocyte cell adhesion molecule,CD166,ALCAM,MEMD, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human CD166 Antigen is produced by our Mammalian expression system and the target gene encoding Trp28-Ala526 is expressed with a human IgG1 Fc tag at the C-terminus.Accession:Q13740. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:82.7 KDa. Background:Activated leukocyte cell adhesion molecule (ALCAM), also named as CD166 and MEMD, is a typeI transmembrane glycoprotein of immunoglobulin superfamily, which mediates homotypic and heterotypic interactions between cells. ALCAM is expressed on thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocytederived dendritic cells. ALCAM mediates low-affinity adhesion with itself or the cysteine-rich scavenger receptor CD6 to regulate T cell development, immunological synapses(IS), and cell migration through endothelial junctions. ALCAM on thymic epithelia mediates adhesion to CD6 on CD4+CD8+ T cells. Adhesion of ALCAM expressing antigen presenting cells and CD6-expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment. ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAML1, both in the developing retina and invasive melanoma.